“…Although current protocols produce human b-like cells with some functionality (Pagliuca et al, 2014;Rezania et al, 2014;Russ et al, 2015), the differentiation efficiency varies greatly among different hPSC lines. For instance, most studies utilize HUES8 (Pagliuca et al, 2014;Veres et al, 2019) or H1 (Ghazizadeh et al, 2017;Rezania et al, 2014) hESCs, which have been shown to be efficient in b cell lineage commitment. The same protocol, when applied to other cell lines, including patient-specific iPSCs, could result in poor b cell specification (Ghazizadeh et al, 2017).…”